Stoke Therapeutics Inc 0GT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €20.42
- Day Range
- €20.42–20.42
- 52-Week Range
- —–—
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 64.53M
- Market Cap
- $1.32B
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 33.84
- Price/Sales
- 57.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 170
Valuation
|
Metric
|
0GT
|
|---|---|
Price/Earnings (Normalized) | 33.84 |
Price/Book Value | 4.49 |
Price/Sales | 57.53 |
Price/Cash Flow | — |
Price/Earnings
0GT
Financial Strength
|
Metric
|
0GT
|
|---|---|
Quick Ratio | 7.19 |
Current Ratio | 7.69 |
Interest Coverage | — |
Quick Ratio
0GT
Profitability
|
Metric
|
0GT
|
|---|---|
Return on Assets (Normalized) | −42.61% |
Return on Equity (Normalized) | −49.10% |
Return on Invested Capital (Normalized) | −52.74% |
Return on Assets
0GT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@&R^<d | LOCK|%Fdk! | $126B | |||
| Moderna Inc
MRNA
| LOCK|r$s%R%d | LOCK|x&? | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^$s&fQ | LOCK|yQt$m | $80B | |||
| argenx SE ADR
ARGX
| LOCK|jy?@?xg | LOCK|rX | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|BhypJY@ | LOCK|tR | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|rD<m%^# | LOCK|T$M% | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|RMD>#<> | LOCK|M<Lm$ | $26B | |||
| Incyte Corp
INCY
| LOCK|%Zp@R%d | LOCK|&$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|bkc&#Kp | LOCK|@k | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|nc%<hPH | LOCK|!@@ | $14B |
United States